AlphAIalphai — Financial news for AI agents
theglobeandmail.comAUG 52 min read$GEHC

GE Healthcare Technologies Inc (GEHC) Gets a Buy from Mizuho Securities

Mizuho Securities analyst Anthony Petrone reiterated a Buy on GE Healthcare Technologies Inc (GEHC) on July 31 and set a $85.00 price target. The article also cites other analyst views, including a July 30 Buy from Stifel and a July 31 Hold from UBS. GEHC reported $5.3B quarterly revenue and $573M net profit for the quarter ended June 30.

Original reporting
theglobeandmail.com
Published Aug 5, 2026, 2:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 5:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
GE Healthcare Technologies Inc (GEHC) Gets a Buy from Mizuho Securities — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$GEHCNeutralLow
01

Why it matters

This is primarily a sell-side sentiment update. The only potentially tradable element is the $85 target reiteration, but there is no new company-specific catalyst beyond previously known earnings context.

02

Market read

Traders may use the $85 target and mixed ratings (Buy vs Hold) for short-term positioning, but the article lacks new guidance or fundamental disclosures.

03

What to watch

The article cites earnings and insider buying, but does not provide fresh guidance, margin drivers, or order-book changes that would justify a larger re-rating.

Relevance 4/10Novelty 3/10Timing: analyst note dated July 31, published Aug 5

Background

The piece summarizes analyst stances (Mizuho Buy with $85 target, Stifel Buy, UBS Hold) and repeats a recent quarter’s revenue and profit figures.

Company-level read

Ticker impact

$GEHCNeutralMedium confidence
Context

Mizuho maintained a Buy on GE Healthcare and set a $85 price target, while UBS held and Stifel also rated Buy.

Expected impact

Likely modest, sentiment-driven volatility around analyst-target headlines rather than a durable repricing.

Evidence & confidence

The newest concrete facts are analyst rating/PT reiterations and a cited prior-quarter earnings snapshot, with no new guidance, contract, or regulatory event disclosed.

Market effects

Sector

Healthcare equipment/diagnostics sentiment may get a small boost from incremental analyst optimism, but no sector-wide policy or demand datapoint is provided.

Regional

No specific regional macro or policy linkage is described.

Global

No global regulatory or supply-chain event is mentioned.

Counterpoint

What could challenge this read

With UBS at Hold, the net signal may be mixed, suggesting limited upside follow-through unless the market is already under-positioned.

Key entities

  • company
    GE Healthcare Technologies Inc

    Subject of the article, with analyst rating and price-target updates plus a cited quarter ending June 30 earnings snapshot.

  • analyst_firm
    Mizuho Securities

    Maintained Buy and set a $85 price target on July 31.

  • analyst_firm
    UBS

    Assigned a Hold rating on July 31.

  • analyst_firm
    Stifel Nicolaus

    Issued a Buy report on July 30.

Read at source← All news

Related articles

AUG 5
$SHOPMed

Shopify surges, AMD slides premarket as earnings disappoint

U.S. stock index futures rose slightly as Strait of Hormuz reopening talks were seen as progressing. Shopify shares jumped 26% after Q2 revenue of $3.58B beat $3.45B, with EPS $0.42 and gross merchandise volume up 32%. AMD shares fell 8.8% on a weaker revenue outlook. SpaceX said it will use Nvidia chips, pressuring AMD and wireless peers.

investing.com6 min
AUG 5
$GEHCMed

5 Insightful Analyst Questions From GE HealthCare’s Q2 Earnings Call

GE HealthCare reported Q2 revenue of $5.30B vs $5.27B estimates and adjusted EPS of $1.13 vs $1.04, with organic revenue up 3.5% and full-year adjusted EPS guidance reiterated at $4.90 (midpoint). Management cited strong orders growth, including Pharmaceutical Diagnostics and Advanced Imaging. Analysts asked about orders sustainability, Flyrcado ramp, PCS stabilization, inflation, and China dynamics.

financialcontent.com6 min
JUL 31
$GEHCMed

GE HealthCare Technologies Inc. Q2 2026 Earnings Call Summary

Strategic Performance Drivers Achieved record organic orders growth of 11.1% and a record backlog of $23.9 billion, driven by healthy end-market demand and successful commercial realignment. Performance was led by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS), which combined for 6.5% growth and 100 basis points of margin expansion.

yahoo.com6 min
JUL 31
$MSFTMed

Stocks Tumble as Chipmakers Plunge, Oil Spikes

US MBA mortgage applications fell -6.4% in the week ended July 24, with the purchase mortgage sub-index down -3.6% and the refinancing mortgage sub-index down -9.9%. The average 30-year fixed rate mortgage rose +7 bp to an 11.5-month high of 6.76% from 6.69% the prior week. The outlook for strong Q2 earnings, which continue this week, is a bullish factor for stocks.

yahoo.com7 min
JUL 30
$GEHCMed

GE HealthCare Technologies Q2 Earnings Call Highlights

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk's Play Adjusted EBIT was $750 million, including $23 million of recognized refunds related to tariffs incurred during the first quarter. Adjusted EBIT margin was 14.2%, down 40 basis points year over year. Adjusted earnings per share rose 6.6% to $1.13, including a $0.04 benefit from tariff refunds and a $0.02 benefit from a lower tax rate compared with the prior year.

yahoo.com6 min
JUL 30
$GEHCMedAI 8/10

GE HealthCare (GEHC) Q2 2026 Earnings Call Transcript

Wednesday, July 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Investor Relations Officer - Carolynne Borders President and Chief Executive Officer - Peter Arduini Vice President and Chief Financial Officer - Jay Saccaro Controller and Chief Accounting Officer - George Newcomb TAKEAWAYS Total Revenue -- $5.3 billion, representing 5.7% growth compared to the prior year.

fool.com8 min